Luseco Drug Interactions

Pharmacodynamic interactions: Antidiabetic drugs (Sulfonylureas, Biguanides, Thiazolidinediones, DPP-4 inhibitors, α-Glucosidase inhibitors, Glinide, GLP-1 receptor agonists, Insulin preparations, etc.): Because these drugs may cause hypoglycemia, they should be administered while closely monitoring plasma glucose and other conditions of patients. In combined use with sulfonylureas, insulin preparations or GLP-1 receptor agonists, dose reduction of these drugs should be considered in order to reduce the risk of hypoglycemia associated with them.
When hypoglycemic symptoms are observed, sucrose is usually administered. When α-glucosidase inhibitors are concomitantly used, glucose should be administered (see Precautions and Adverse Reactions).
Diuretics (Loop diuretics, Thiazide diuretics, etc.): Because diuretic action can be enhanced in combined use with luseogliflozin, caution should be exercised by, for example, adjusting the dose of diuretics as needed (see Precautions).
Pharmacokinetic interactions: Metabolism of luseogliflozin was shown to mainly involve CYP3A4/5, 4A11, 4F2, 4F3B and UGT1A1 (in vitro).
Luseogliflozin showed weak inhibitory effect on CYP2C19 (IC₅₀ value: 58.3 μmol/L), while it did not show any inhibitory effect on CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, or 3A4 (IC₅₀ > 100 μmol/L) (in vitro). Luseogliflozin was shown not to induce CYP1A2 or 2B6, but to weakly induce CYP3A4 (in vitro). In a study in patients with type 2 diabetes mellitus using urinary 6β-hydroxycortisol concentration as a marker, luseogliflozin did not induce CYP3A4 (data in non-Japanese subjects).
Effect of other medicinal products on luseogliflozin: Interaction in combined use of luseogliflozin and 6 representative existing oral hypoglycemic drugs (glimepiride, metformin, voglibose, miglitol, pioglitazone, and sitagliptin) was investigated in healthy Japanese male adults. Pharmacokinetics of luseogliflozin was considered not to be influenced greatly by other drugs used concomitantly.
Effects of luseogliflozin on other medicinal products: Interaction in combined use of luseogliflozin and 6 representative existing oral hypoglycemic drugs (glimepiride, metformin, voglibose, miglitol, pioglitazone, and sitagliptin) was investigated in healthy Japanese male adults. Luseogliflozin was considered not to greatly influence the pharmacokinetics of other drugs used in combination with luseogliflozin.
Drug/Laboratory test interference: 1,5-AG assay: Due to the mechanism of action of luseogliflozin, urinary glucose becomes positive and serum 1,5-AG (1,5-anhydroglucitol) is decreased during its administration. It should be noted that the test results of urinary glucose and serum 1,5-AG do not reflect plasma glucose control.